跳至主要内容
临床试验/NCT00175149
NCT00175149终止4 期

The Efficacy of 1,25 Dihydroxycholecalciferol on the Cardiovascular System in Patients With Renal Dysfunction

Per Ivarsen1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2002年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
发起方
入组人数
24
试验地点
1
主要终点
The effect of dihydroxycholecalciferol on left ventricular hypertrophy

研究概览

简要总结

Left ventricular hypertrophy (LVH) predicts mortality at start of dialysis. Prevention of of LVH is important. It is not known whether secondary hyperparathyroidism might induce LVH. In the present study patients are randomised to 1.25 dihydroxycholecalciferol or no treatment to study the effect on LVH.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Chronic kidney disease (S-creatinin > 150 and < 600 mikroM)
  • Secondary hyperparathyroidism (Between 3-8 times the upper limit of our PTH assay)
  • Stable blood pressure during the last 6 months (less than (160/95)
  • B-hemoglobin > 6 mmol/l
  • EKG with sinus rhythm and no sign of Q-wave infarction
  • Expected follow up 6 month

排除标准

  • Pregnancy
  • Kidney transplantation
  • Malignant disease

研究组 & 干预措施

1

Active Comparator

Given alfacalcidiol. Dose adjusted after PTH level

干预措施: Alfacalcidiol (Drug)

结局指标

主要结局

The effect of dihydroxycholecalciferol on left ventricular hypertrophy

时间窗: 6 month

次要结局

  • Changes in the activity of the renin-angiotensin system(6 month)
  • Changes in left ventricular function(6 month)

研究者

发起方
Per Ivarsen
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Per Ivarsen

Consultant

Aarhus University Hospital

研究点 (1)

Loading locations...

相似试验

Active Vitamin D Effect on Left Ventricular... | 临床试验